Jacksonville, FL, Oct. 22, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- mCig Inc., (MCIG), a diversified company servicing the legal cannabis markets, is pleased to announce that its laboratory in Europe is close to completion of new CBD-infused topical line. mCig plans to use its producer, processor and distributor licenses in California to roll out the line, which will also include a 1:1 CBD and THC topical product. Distribution efforts will be focused around mCig’s online distribution channels, as well as healthcare and wellness professionals.
mCig, Inc.’s new pain formulation is for everyone who needs relief, whether it be from a hard workout, or just the tension that comes from the stresses of everyday life. The proprietary combination of natural ingredients is perfect for anyone experiencing localized pain, muscle soreness or joint pain and stiffness. Whole hemp CBD isolate is combined with a host of other all natural herbal ingredients to provide a cooling, soothing, and calming effect.
CBD is well known for its anti-inflammatory properties and is used by millions who wish to alleviate muscle and joint pain. Menthol provides the cooling sensation that brings circulation to the area and helps heal the muscles. Camphor and tea tree oil are common treatments for relieving pain and reducing inflammation. Aloe and vitamin E work to moisturize and protect the skin.
“We are excited to announce the expansion of our CBD offerings to include topical pain management products. We will continue to expand our CBD portfolio to include new, cutting-edge products. We expect that our pain formulations will be enthusiastically received by our partners and customers,” said Paul Rosenberg, CEO.
About MCIG Group (MCIG)
Headquartered in Jacksonville, Florida, mCig, Inc. (MCIG) is a diversified company servicing the legal cannabis, hemp, and CBD markets via its lifestyle brands. mCig, Inc. is committed to being the leading distributor of technology, products, and services to fit the needs of a rapidly expanding industry.
Safe Harbor Statement:
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies.
This release contains a non-GAAP disclosure, EBIDTA, which consists of net income plus interest expense, net, provision for income taxes and depreciation and amortization. This term, as the Company defines it, may not be comparable to a similarly titled measure used by other companies and is not a measure of performance presented in accordance with GAAP. The Company uses EBIDTA as a measure of operating performance. EBIDTA should not be considered as a substitute for net income.